Antisense oligonucleotide nanocapsules efficiently inhibit EWS-Fli1 expression in a Ewing's sarcoma model

Oligonucleotides

Volumn 16, Issue 2, 2006, Pages 158-168

  Toub, Nedjma ^a,b   Bertrand, Jean Rémi ^b   Malvy, Claude ^b   Fattal, Elias ^a   Couvreur, Patrick ^a  

^a UNIV PARIS SUD   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CYANOACRYLATE DERIVATIVE; NANOCAPSULE; NUCLEASE; POLYISOBUTYLCYANOACRYLATE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FLI1; UNCLASSIFIED DRUG;

ANIMAL CELL; AQUEOUS SOLUTION; ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CONFOCAL MICROSCOPY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG UPTAKE; ENCAPSULATION; EWING SARCOMA; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33745209210     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2006.16.158     Document Type: Article

References (27)

1. ARVAND, A., BASTIANS, H., WELFORD, S.M., THOMPSON, A.D., RUDERMAN, J.V., and DENNY, C.T. (1998). EWS/FLI1 upregulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene 17, 2039-2045.
2. AYNIE, I., VAUTHIER, C., FOULQUIER, M., MALVY, C., FATTAL, E., and COUVREUR, P. (1996). Development of a quantitative polyacrylamide gel electrophoresis analysis using a multichannel radioactivity counter for the evaluation of oligonucleotide-bound drug carrier. Anal. Biochem. 240, 202-209.
3. BAILLY, R.A., BOSSELUT, R., ZUCMAN, J., CORMIER, F., DELATTRE, O., ROUSSEL, M., et al. (1994). DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol. Cell. Biol. 14, 3230-3241.
4. BECK, P., KREUTER, J., RESZKA, R., and FICHTNER, I. (1993). Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models. J. Microencapsulation 10, 101-114.
5. CHAVANY, C., SAISON-BEHMOARAS, T., LE DOAN, T., PUISIEUX, F., COUVREUR, P., and HÉLÈNE C. (1994). Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 11, 1370-1378.
6. COUVREUR, P., GRISLAIN, L., LENEARTS, V., BRASSEUT, F., GUIOT, P., and BIERNACKI, A. (1986). Biodegradable polymeric nanoparticles as drug carrier for antitumor agents. In: Polymeric Nanoparticles and Microspheres. P. Guiot, P. Couvreur, eds. (CRC Press, Boca Raton, FL, pp. 27-93.
7. COUVREUR, P., KANTE, B., GHISLAIN, L., ROLAND, M., and SPEISER, P. (1982). Toxicity of polyalkylcyanoacrylate nanoparticles. 1: Free nanoparticles. J. Pharm. Sci. 71, 786-790.
8. DELATTRE, O., ZUCMAN, J., PLOUGASTE, B., DESMAZE, C., MELOT, T., PETER, M., et al. (1992). Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162-165.
9. DESMAZE, C., ZUCMAN, J., DELATTRE, O., THOMAS, G., and AURIAS, A. (1992). Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors. Genes Chromosomes Cancer 5, 30-34.
10. HU-LIESKOVAN, S., ZHANG, J., WU, L., SHIMADA, H., SCHOFIELD, D., and TRICHE, T. (2005). EWS-Fli1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res. 65, 4633-4644.
11. LAMBERT, G., BERTRAND, J.R., FATTAL, E., SUBRA, F., PINTO-ALPHANDARY, H., MALVY, C., AUCLAIR, C., and COUVREUR, P. (2000a). EWS Fli-1 antisense nanocapsules inhibit Ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279, 401-406.
12. LAMBERT, G., FATTAL, E., PINTO-ALPHANDARY, H., GULIK, A., and COUVREUR, P. (2000b). Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharm. Res. 17, 707-714.
13. LENAERTS, V., COUVREUR, P., CHRISTIAENS-LEYH, D., JOIRIS, E., ROLAND, M., ROLLMAN, B., and SPEISER, P. (1984). Identification and study of a degradation way for polyisobutylcyanoacrylate nanoparticles. Biomaterials 5, 65-68.
14. LEVIN, A.A. (1999). A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys. Acta 1489, 69-84.
15. MANIATIS, T., FRITSCH, E.F., and SAMBROOK, J. (1982). Molecular Cloning. A Laboratory Manual. (Cold Spring Harbor Laboratory, Cold Spring, NY).
16. MATSUMOTO, Y., TANAKA, K., NAKATANI, F., MATSUNOBU, T., MATSUDA, S., and IWAMOTO, Y. (2001). Downregulation and forced expression of EWS-Fli1 fusion gene result in changes in the expression of G(1) regulatory genes. Br. J. Cancer 84, 768-775.
17. MULLER, R.H., LHERM, C., HERBORT, J., and COUVREUR, P. (1990). In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials 11, 590-595.
18. NAKATA, Y., KIM, T., SHETZLINE, S., and GERWITZ, A. (2005). Nucleic acid modulation of gene expression: Approaches for nucleic acid therapeutics against cancer. Crit. Rev. Eukaryotic Gene Expression 15, 163-182.
19. PRIEUR, A., TIRODE, F., COHEN, P., and DELATTRE, O. (2004). EWS/FLI1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell. Biol. 24, 7275-7283.
20. SILIGAN, C., BAN, J., BACHMAIER, R., SPAHN, L., KREPPEL, M., SCHAEFER, K., POREMBA, C., ARYEE, D., and KOVAR, H. (2005). EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin. Oncogene 24, 2512-2524.
21. SMITH, F.E. (1951). Tetrazolium salt. Science 113, 751-754.
22. STEPHENSON, M.L., and ZAMECNIK, P.C. (1978). Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 285-288.
23. TANAKA, K., IWAKURA, T., HARIMAYA, K., SATO, H., and IWAMOTO, Y. (1997). EWS-Fli-1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Invest. 99, 239-247.
24. TORCHILIN, V.P., ZHOU, F., and HUANG, L. (1993). pH-sensitive liposomes. J. Liposome Res. 3, 201-255.
25. TOUB, N., ANGIARI, C., EBOUÉ, D., FATTAL, E., TENU, J.-P., LE DOAN, T., and COUVREUR, P. (2005). Cellular fate of oligonucleotides when delivered by nanocapsules of poly(isobutylcyanoacrylate. J. Control. Release 106, 209-213.
26. TOUB, N., BERTRAND, J.-R., TAMADDON, A., ELHAMESS H, HILLAIREAU H, MARSIMENKO A, MACCARIO J, MALVY, C., FATTAL, E., and COUVREUR, P. (2006). Efficacy of siRNA-nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma. Pharm. Res. 23, 892-900.
27. WATNASIRICHAIKUL, S., DAVIES, N.M., RADES, T., and TUCKER, I.G. (2000). Preparation of biodegradable insulin nanocapsules from biocompatible microemulsion. Pharm. Res. 17, 684-689.